CD44 and breast cancer: Interestingly, recent evidence demonstrated that RHAMM is more sensitive to the density of HA than CD44 in breast cancer cell lines, and its surface expression can be enhanced to compensate the pro‐tumorigenic signaling mediated by CD44 when CD44 is blocked [82].